Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 781 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... August 16, 2021 Group of Breast Cancer Survivors is Finding New Strength from Fitness... May 11, 2021 Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation June 5, 2024 Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical... December 20, 2022 Load more HOT NEWS Nomination Process for the 2026 ESMO Society Awards Now Open FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead...
